“. We reiterate our Overweight rating and 12-month price target of $68. This morning, TSRO presented an updated GARNET study (anti- PD1 TSR-042) results in 2nd line NSCLC patients and also initial safety results from the anti-LAG-3 agent TSR-033 in poster presentations at the ongoing SITC annual meeting. Overall, the GARNET data reported improved response rates in a larger cohort size of 2nd line NSCLC patients and TSR-042 activity profile in this setting looks compelling so far. The anti-LAG-3 initial safety data were largely in- line with the published abstract.”
According to TipRanks.com, Young is a 4-star analyst with an average return of 4.6% and a 47.5% success rate. Young covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Puma Biotechnology, and Intercept Pharma.
Tesaro has an analyst consensus of Moderate Buy, with a price target consensus of $52.50, a 70.8% upside from current levels. In a report issued on October 29, H.C. Wainwright also maintained a Buy rating on the stock with a $69 price target.
Based on Tesaro’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $137 million. In comparison, last year the company had a GAAP net loss of $25.28 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.